Ibogaine attracts a great deal of speculation. Search for almost any condition alongside its name and you will find someone claiming it helps — Parkinson’s disease, nicotine addiction, gambling, OCD, chronic pain, autoimmune conditions.
Most of those claims have no clinical evidence behind them. Some have a plausible mechanism and no data. A few describe things that would actually rule you out of treatment rather than qualify you for it.
This page goes through them honestly. Where there is a rationale we say so; where there is nothing, we say that too — including for conditions we are regularly asked to arrange treatment for.
How to think about this
One pattern explains most of the confusion.
Ibogaine acts on an unusually wide range of receptor systems, and it produces effects — reduced compulsion, a prolonged introspective state, reported changes in outlook — that are broad rather than specific. It is therefore easy to construct a plausible-sounding argument for almost any condition involving compulsion, mood or neurological function.
Plausible arguments are not evidence. Ibogaine’s clinical evidence base is small and concerns substance dependence: the published studies covered alcohol, cannabis, cocaine and crack. Everything beyond that is extrapolation, and the further you go from dependence, the thinner it becomes.
Condition by condition
| Condition | Status | What we would say |
|---|---|---|
| Nicotine / smoking | Rationale, no evidence | Ibogaine acts on nicotinic receptors among others, so the mechanism is arguable. There is no clinical evidence for it as a smoking-cessation treatment, and we would not recommend travelling for that purpose alone. Notably, patients are asked not to smoke around treatment. |
| Gambling, gaming, compulsive behaviours | Treated by some clinics; evidence thin | The reasoning is by analogy with substance compulsion, and some programmes accept these patients. Published outcome data does not exist. Reasonable to discuss; not something to expect certainty about. |
| Eating disorders | Case by case; caution | Compulsive component makes the analogy tempting, but eating disorders carry their own medical risks — particularly electrolyte disturbance, which is directly relevant to cardiac safety. Requires specialist assessment, not enthusiasm. |
| OCD | Minimal data | Occasional interest, no meaningful clinical evidence. Established treatments should come first. |
| Depression, PTSD, trauma | Early research | The most active area outside addiction. Strongest where it accompanies dependence. See the full page → |
| Traumatic brain injury | Early research | Studies in veterans have reported symptom improvements, but the work is early and we make no claims about treating TBI. See veterans page → |
| Parkinson’s disease | Exclusion criterion | Frequently asked about because of preclinical interest in neuroplasticity. In the published treatment protocol, Parkinson’s disease is an explicit exclusion — patients with it are not treated. |
| Alzheimer’s / dementia | Exclusion criterion | Also an explicit exclusion in the published protocol. |
| Bipolar disorder | Caution / usually excluded | A risk consideration rather than an indication. Psychosis and schizophrenia are contraindications without exception. |
| Epilepsy / seizure disorders | Serious caution | Requires specialist assessment; seizure history is a significant complicating factor, not a target. |
| Diabetes | Exclusion if uncontrolled | Uncontrolled diabetes is an explicit exclusion criterion — controlling it is a prerequisite, not a treatment goal. |
| ALS, multiple sclerosis, autoimmune conditions | No basis | No clinical evidence supports ibogaine for these. We do not arrange treatment on this basis. |
| Chronic pain, fibromyalgia | No basis | Occasionally claimed, not supported. Where opioid dependence has developed from pain management, the dependence is the treatable part. |
| Lyme disease, “parasites”, cancer, long COVID | No basis | No evidence whatsoever. Any provider offering ibogaine for these is one to avoid entirely. |
The Parkinson's paradox
One entry above deserves expanding, because it illustrates the whole problem.
“Does ibogaine treat Parkinson’s disease?” is among the most common questions we receive in this category. The interest is not baseless: there is preclinical research into whether ibogaine promotes neuroplasticity and affects neurotrophic factors, and that research is legitimately interesting.
But in the published clinical protocol, Parkinson’s disease is an exclusion criterion — patients with it are not accepted for treatment.
The gap between a laboratory hypothesis and a treatment a person can safely receive is the entire distance this field has to travel. Preclinical promise is a reason to fund research. It is not a reason to fly somewhere and take a compound with cardiac risks for a condition nobody has shown it treats.
When "other conditions" are really the same condition
A significant number of enquiries in this category turn out to describe dependence wearing different clothes.
Someone asking about ibogaine for chronic pain is often dependent on the opioids prescribed for it. Someone asking about anxiety has frequently been drinking to manage it for years. Someone asking about “compulsive behaviour” describes a pattern that includes a substance.
Where that is the case, the picture changes: dependence is what ibogaine has actually been studied for, and there is real ground to stand on.
This is worth raising when you contact us — not because we are trying to reframe your problem, but because the honest answer often differs depending on which of these is underneath.
Why we say no
We are not a clinic, and we keep the list of conditions we help with short on purpose: there is a strong ethical reason not to expand it.
So we decline enquiries regularly, including from people who are willing to pay and want to proceed. If someone travels for a condition ibogaine has never been shown to treat, they take on a genuine cardiac risk for no expected benefit, and lose money and time they may not have.
A clinic that treats everything treats nothing carefully. The same applies to advisories.
How to choose an ibogaine clinic →
If your condition isn't listed
Ask us. We will tell you what is actually known — including, most of the time, that the honest answer is “there is no evidence for that, and we would not recommend it”.
If dependence is part of the picture, we will say that too, and explain what treatment would realistically involve.
Free and confidential. We’ll give you the honest position, including when the answer is no — usually within 24 hours.